Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Shooting of MIT professor Nuno Loureiro has police searching for a suspect - 2The most effective method to Help a Friend or family member Determined to have Cellular breakdown in the lungs
- 3The Best Cell phone Brands for Tech Lovers
- 4Find the Insider facts of Compelling Systems administration: Building Associations for Progress
- 5Instructions to Boost Your True capacity with a Brain research Degree
- The Best Traditional Music Arrangers in History
- The 2026 'Super Bowl of Astronomy' starts today — here's what's happening
- 7 Heavenly Espressos, One Do You Like?
- The Most Encouraging New companies to Look Out For
- A few Exemplary Chinese Dishes, Which Are Famous Around the world
- Truly amazing Palaces: Which Is Your Number one?
- Some gifted dogs can learn new toy names by eavesdropping on owners
- Ocean side Objections: Staggering Waterfront Breaks
- Young Muslims in Germany feel left out of Mideast debate, experts say
